US EditionCuts, ousters and drama at the FDA
- Scott Steele has been named the acting head of the Center for Biologics Evaluation and Research after Peter Marks left the FDA, according to an FDA statement on April 1.
- Marks expressed concerns over Health and Human Services Secretary Robert F. Kennedy Jr.'s approach to vaccines, mentioning a lack of support for truth and transparency in his resignation letter.
- Health and Human Services plans to cut about 20,000 jobs, a 24% workforce reduction, amidst layoffs at several agencies.
- Dr. Martin Makary, newly confirmed as FDA Director, hired Tracy Beth Hoeg, a critic of federal COVID research, as a special assistant.
Insights by Ground AI
Does this summary seem wrong?
11 Articles
11 Articles
All
Left
2
Center
2
Right
3
FDA Names New Acting Vaccine Leader After Previous Chief’s Departure
After its top vaccine official left the Food and Drug Administration (FDA), the agency announced Tuesday that it has named his replacement. In an April 1 statement on X, the FDA said Scott Steele would be the acting head of the Center for Biologics Evaluation and Research (CBER), which Peter Marks once led. “Dr. Steele is a science, technology, and policy professional at FDA with extensive experience in multiple disciplines, including emerging s…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources11
Leaning Left2Leaning Right3Center2Last UpdatedBias Distribution43% Right
Bias Distribution
- 43% of the sources lean Right
43% Right
L 29%
C 29%
R 43%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
